Advaxis, Inc. Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immunotherapy for HER2 Expressing Cancers

Published: Oct 11, 2011

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB:ADXS) a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.

Back to news